Cefaclor Extended-Release Tablets Rx
Generic Name and Formulations:
Cefaclor 375mg, 500mg; ext-rel tabs.
Various generic manufacturers
Indications for Cefaclor Extended-Release Tablets:
Susceptible mild to moderate infections including acute exacerbations of chronic bronchitis, secondary infections of acute bronchitis, pharyngitis/tonsillitis, uncomplicated skin and skin structures.
Take with meals. Swallow whole. Cefaclor ext-rel tab 500mg twice daily clinically equivalent to caps 250mg three times daily. ≥16yrs: Bronchitis: 500mg every 12 hrs for 7 days. Pharyngitis/tonsillitis: 375mg every 12 hrs for 10 days. Skin and skin structures: 375mg every 12 hrs for 7–10 days.
<16yrs: not recommended.
Penicillin or other allergy. Discontinue if colitis occurs and treat. Severe renal dysfunction. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.
May cause false (+) Coomb's test or glucose test with Clinitest or Benedict's or Fehling's soln. Potentiated by probenecid. Monitor warfarin. ER: antagonized by concomitant (within 1 hr) aluminum or magnesium-containing antacids.
Headache, GI upset, rash, blood dyscrasias, hepatic dysfunction, cough, CNS stimulation, serum-sickness-like reactions.
Formerly known under the brand names Ceclor CD (ext-rel tabs); Ceclor (caps, susp); Raniclor (caps).
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Prazosin May Be Effective as Treatment for Alcohol Use Disorder
- Panel Recommends Earlier Body Weight Monitoring in Use of Mood Stabilizers
- Nondaily Cigarette Use Increasing Among Individuals With Mental Health, Substance Use Disorders
- Cesarean Delivery, Early Childhood Antibiotic Use Not Associated With Risk for ADHD
- Uncertainty as a Form of Violence: Current Immigration Policy and Crisis
- FDA Gets Tough on Juul, Other Electronic Cigarette Makers